Oxurion NV has a total of 16 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2003. It filed its patents most often in Australia, EPO (European Patent Office) and Hungary. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and foods and drinks are TALENGEN INST LIFE SCIENCES CO LTD, OXTHERA INC and TAMIR BIOTECHNOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 3 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Hungary | 2 | |
#4 | Norway | 2 | |
#5 | Canada | 1 | |
#6 | Morocco | 1 | |
#7 | Serbia | 1 | |
#8 | Singapore | 1 | |
#9 | United States | 1 | |
#10 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Foods and drinks | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Enzymes | |
#5 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Pedersen Ove | 9 |
#2 | Vermassen Elke | 9 |
#3 | Jonckx Bart | 3 |
#4 | Van Bergen Tine | 3 |
#5 | Pakola Steve | 3 |
#6 | Feyen Jean | 2 |
#7 | Smet Marc De | 2 |
#8 | Stalmans Ingeborg | 1 |
#9 | De Smet Marc | 1 |
Publication | Filing date | Title |
---|---|---|
US2020055849A1 | Integrin antagonists | |
MA51342B1 | Integrin antagonists | |
AU2017231765A1 | Posterior ocular fibrosis inhibition by antagonizing placental growth factor | |
AU2012321082A1 | Improving trabeculectomy outcome |